CRISPR Therapeutics (CRSP) Competitors $62.32 -0.62 (-0.99%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$62.05 -0.27 (-0.43%) As of 08:39 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRSP vs. ALLO, AXSM, BEAM, EDIT, KALA, MRNA, NTLA, VRTX, GMAB, and SMMTShould you be buying CRISPR Therapeutics stock or one of its competitors? The main competitors of CRISPR Therapeutics include Allogene Therapeutics (ALLO), Axsome Therapeutics (AXSM), Beam Therapeutics (BEAM), Editas Medicine (EDIT), KALA BIO (KALA), Moderna (MRNA), Intellia Therapeutics (NTLA), Vertex Pharmaceuticals (VRTX), Genmab A/S (GMAB), and Summit Therapeutics (SMMT). These companies are all part of the "medical" sector. CRISPR Therapeutics vs. Its Competitors Allogene Therapeutics Axsome Therapeutics Beam Therapeutics Editas Medicine KALA BIO Moderna Intellia Therapeutics Vertex Pharmaceuticals Genmab A/S Summit Therapeutics Allogene Therapeutics (NASDAQ:ALLO) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Do insiders and institutionals believe in ALLO or CRSP? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, ALLO or CRSP? Allogene Therapeutics has higher earnings, but lower revenue than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene TherapeuticsN/AN/A-$257.59M-$1.11-1.05CRISPR Therapeutics$35M161.94-$366.25M-$5.43-11.48 Does the media refer more to ALLO or CRSP? In the previous week, CRISPR Therapeutics had 14 more articles in the media than Allogene Therapeutics. MarketBeat recorded 15 mentions for CRISPR Therapeutics and 1 mentions for Allogene Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.69 beat Allogene Therapeutics' score of 0.59 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ALLO or CRSP? Allogene Therapeutics has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500. Do analysts prefer ALLO or CRSP? Allogene Therapeutics presently has a consensus price target of $8.44, indicating a potential upside of 627.97%. CRISPR Therapeutics has a consensus price target of $71.50, indicating a potential upside of 14.73%. Given Allogene Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Allogene Therapeutics is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.75CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is ALLO or CRSP more profitable? Allogene Therapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene TherapeuticsN/A -55.99% -42.75% CRISPR Therapeutics -1,229.43%-20.05%-17.09% SummaryAllogene Therapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRSP vs. The Competition Export to ExcelMetricCRISPR TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.67B$3.15B$5.80B$10.44BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-11.4821.0580.5126.85Price / Sales161.94397.51520.52163.30Price / CashN/A44.8326.0131.15Price / Book2.759.6215.746.42Net Income-$366.25M-$53.02M$3.30B$271.73M7 Day Performance7.75%1.43%3.93%2.82%1 Month Performance14.73%3.42%5.30%6.60%1 Year Performance29.35%11.20%80.46%28.60% CRISPR Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRSPCRISPR Therapeutics2.9288 of 5 stars$62.32-1.0%$71.50+14.7%+29.3%$5.67B$35M-11.48460High Trading VolumeALLOAllogene Therapeutics2.8139 of 5 stars$1.16+2.2%$8.44+631.1%-58.6%$251.83M$20K-1.02310AXSMAxsome Therapeutics4.8557 of 5 stars$117.45-0.8%$177.86+51.4%+21.0%$5.84B$385.69M-23.08380BEAMBeam Therapeutics2.9945 of 5 stars$21.01+2.0%$46.40+120.9%-5.2%$2.13B$63.52M-4.68510EDITEditas Medicine3.9643 of 5 stars$2.68-0.6%$5.10+90.7%-24.9%$241.44M$32.31M-0.94230KALAKALA BIO4.3074 of 5 stars$17.84-4.2%$21.75+21.9%+239.0%$125.69M$3.89M-2.6430Analyst RevisionHigh Trading VolumeMRNAModerna4.4671 of 5 stars$23.76+1.1%$41.81+76.0%-61.6%$9.22B$3.24B-3.155,800NTLAIntellia Therapeutics4.4592 of 5 stars$11.47+0.4%$27.11+136.5%-28.7%$1.23B$57.88M-2.44600Trending NewsAnalyst ForecastVRTXVertex Pharmaceuticals4.9068 of 5 stars$394.68+0.0%$496.05+25.7%-17.6%$101.03B$11.02B28.176,100Positive NewsAnalyst RevisionGMABGenmab A/S3.6008 of 5 stars$27.99+0.6%$39.25+40.3%+10.8%$17.96B$3.12B14.072,682SMMTSummit Therapeutics3.1795 of 5 stars$18.79-0.8%$33.79+79.8%-22.6%$13.94BN/A-18.58110 Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Axsome Therapeutics Alternatives Beam Therapeutics Alternatives Editas Medicine Alternatives KALA BIO Alternatives Moderna Alternatives Intellia Therapeutics Alternatives Vertex Pharmaceuticals Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRSP) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThis Crypto Could Thrive as Global Tensions Rise Right as capital begins to rotate back into crypto, my top...Crypto 101 Media | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts